Peter J Allen
Overview
Explore the profile of Peter J Allen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
392
Citations
18118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raji S, Zaribafzadeh H, Jones T, Kanu E, Tong K, Fletcher A, et al.
medRxiv
. 2025 Feb;
PMID: 39974026
Introduction: While mutations represent the primary oncogenic driver in pancreatic ductal adenocarcinoma (PDAC), the association between codon-specific alterations and patient outcomes remains poorly elucidated, largely due to a lack of...
2.
Iyer M, Fletcher A, Okoye J, Shi C, Chen F, Kanu E, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39969959
Purpose: Intraductal papillary mucinous neoplasms (IPMN) occur in 5-10% of the population, but only a small minority progress to pancreatic ductal adenocarcinoma (PDAC). The lack of accurate predictors of high-risk...
3.
Schleimer L, Liu A, Kalvin H, Barekzai A, Choubey A, Jung J, et al.
Ann Surg Oncol
. 2025 Jan;
PMID: 39875717
Background: A growing number of centers offer hepatic artery infusion pump (HAIP) chemotherapy for advanced liver malignancies. While small series have demonstrated feasibility of robotic HAIP placement, comparison of outcomes...
4.
Sharib J, Rhodin K, Liu A, McIntyre S, Bartholomew A, Masoud S, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2501-2502.
PMID: 39873846
No abstract available.
5.
Sharib J, Rhodin K, Liu A, McIntyre S, Bartholomew A, Masoud S, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2456-2466.
PMID: 39827317
Background: Randomized data suggest improved survival with adjuvant chemotherapy for biliary tract cancers; however, subset analyses of intrahepatic cholangiocarcinoma (IHC) show limited survival benefit. This study evaluated the impact of...
6.
Liu A, Lowe M, Niedzwiecki D, Rhodin K, Sharib J, Wildman-Tobriner B, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2508-2509.
PMID: 39743650
No abstract available.
7.
Blair A, Radomski S, Chou J, Liu M, Howell T, Park W, et al.
Ann Surg Oncol
. 2024 Nov;
32(3):1869-1878.
PMID: 39576455
Background: Pancreatic acinar cell carcinoma (pACC) is a rare neoplasm of the exocrine pancreas. There is a dearth of information about tumor characteristics and patient outcomes. This study describes the...
8.
Liu A, Lowe M, Niedzwiecki D, Rhodin K, Sharib J, Wildman-Tobriner B, et al.
Ann Surg Oncol
. 2024 Nov;
32(2):1033-1042.
PMID: 39565488
Background: Hepatic arterial infusion (HAI) is an established treatment for patients with unresectable colorectal liver metastases (uCRLM). Until recently, HAI was only performed at a limited number of centers. We...
9.
Iyer M, Fletcher A, Shi C, Chen F, Kanu E, Eckhoff A, et al.
bioRxiv
. 2024 Nov;
PMID: 39554015
Purpose: Intraductal papillary mucinous neoplasms (IPMN) occur in 5-10% of the population, but only a small minority progress to pancreatic ductal adenocarcinoma (PDAC). The lack of accurate predictors of high-risk...
10.
Gardner T, Park W, Allen P
Gastroenterology
. 2024 Sep;
168(1):186-187.
PMID: 39284556
No abstract available.